A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAL0139 tablets in Chinese adult health study participants with multiple doses.
Latest Information Update: 20 Mar 2026
At a glance
- Drugs SAL 0139 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
Most Recent Events
- 20 Mar 2026 New trial record